9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 662

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Overall survival,  Number of participants with adverse events characterized as Grade 3/4 according to the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE),  Progression-free survival, Objective response rate

Interventions: vorinostat, Placebo

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double,Primary Purpose: Treatment

Primary Completion Date: July 2011

Completion Date: November 2011

Last  Posted Date: April 20, 2015

Location:

Website Link: https://ClinicalTrials.gov/show/NCT00128102

Was this article helpful?
Dislike 0